Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Development of Novel Small Molecule Therapeutics for Alzheimer's Disease through Targeting Arginine Metabolism
FY 2024-25
Summary
Alzheimer's disease (AD) is a disorder that destroys brain cells, causing cognition and memory to deteriorate over time. More than 500,000 Canadians over age 65 have cognitive decline due to AD. Unfortunately, due to the complex pathogenesis of AD, limited medications are available, and available drugs are only symptomatic, not curative. The build-up of toxic amyloid-beta (Ab) proteins in the brain has been a major hypothesis and treatment target for AD. However, various therapies that target Ab failed to improve AD. Recently, inflammation of brain cells (neuroinflammation) is proposed as a new direction for developing AD treatments. Inflammation can be targeted through the arginine metabolic pathway by either inhibition of an enzyme (arginase) or mimicking a metabolic by-product (fumarate). I aim to design, prepare and evaluate novel fumarate analogues and arginase inhibitors as potential AD therapeutics. I have already prepared 75 fumarate analogues and 50 arginase inhibitors through synthetic protocols. In future, I will identify active fumarate analogues and arginase inhibitors by monitoring their inhibition activities on respective targets (Keap1/arginase), using chemicals that produce light signals when bound to targets. Subsequently, I will use computational software to understand their interactions with Keap1 or arginase. I will then administer the active compounds into a standard mouse model to analyze normal body's response. Lastly, I will administer the top compounds to an AD transgenic mouse model to determine their efficacy, by measuring the levels of neuroinflammation markers. I anticipate that this study will lead to the discovery of potential AD drugs that target arginine metabolism. These outcomes will also help understand the role of arginine metabolism in AD and open new directions for future drug research.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
518274
Name
Lee Yui Sun Marvick
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of Novel Small Molecule Therapeutics for Alzheimer's Disease through Targeting Arginine Metabolism
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Arginine Metabolism; Drug Development; Medicinal Chemistry; Neuroinflammation
Abstract
Alzheimer's disease (AD) is a disorder that destroys brain cells, causing cognition and memory to deteriorate over time. More than 500,000 Canadians over age 65 have cognitive decline due to AD. Unfortunately, due to the complex pathogenesis of AD, limited medications are available, and available drugs are only symptomatic, not curative. The build-up of toxic amyloid-beta (Ab) proteins in the brain has been a major hypothesis and treatment target for AD. However, various therapies that target Ab failed to improve AD. Recently, inflammation of brain cells (neuroinflammation) is proposed as a new direction for developing AD treatments. Inflammation can be targeted through the arginine metabolic pathway by either inhibition of an enzyme (arginase) or mimicking a metabolic by-product (fumarate). I aim to design, prepare and evaluate novel fumarate analogues and arginase inhibitors as potential AD therapeutics. I have already prepared 75 fumarate analogues and 50 arginase inhibitors through synthetic protocols. In future, I will identify active fumarate analogues and arginase inhibitors by monitoring their inhibition activities on respective targets (Keap1/arginase), using chemicals that produce light signals when bound to targets. Subsequently, I will use computational software to understand their interactions with Keap1 or arginase. I will then administer the active compounds into a standard mouse model to analyze normal body's response. Lastly, I will administer the top compounds to an AD transgenic mouse model to determine their efficacy, by measuring the levels of neuroinflammation markers. I anticipate that this study will lead to the discovery of potential AD drugs that target arginine metabolism. These outcomes will also help understand the role of arginine metabolism in AD and open new directions for future drug research.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lee, Yui Sun Marvick
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~